Fig. 1: Survival and response to treatment.
From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
a, Patient flow in trial. b, Waterfall plot that displays the maximal change in tumor size for all patients who received full-dose DNX-2401 treatment (n = 42). Bars represent the maximal tumor change from baseline on the basis of contrast-enhanced MRI. Bars are colored according to responses classified according to mRANO criteria. c, Survival for each patient by DNX-2401 dose. The bar colors show the response to treatment according to the mRANO criteria. Arrows indicate that the patient remains alive. d, Overall survival for the intent to treat population. Crosses denote censored data.
